UA85686C2 - Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения - Google Patents
Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его полученияInfo
- Publication number
- UA85686C2 UA85686C2 UAA200603253A UAA200603253A UA85686C2 UA 85686 C2 UA85686 C2 UA 85686C2 UA A200603253 A UAA200603253 A UA A200603253A UA A200603253 A UAA200603253 A UA A200603253A UA 85686 C2 UA85686 C2 UA 85686C2
- Authority
- UA
- Ukraine
- Prior art keywords
- methyl
- carbonyl
- medicament
- enylaminomethyl
- hexyloxycarbonylamidino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyridine Compounds (AREA)
Abstract
Заявка касается метансульфоната этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1-метил-1H-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты в кристаллических модификациях І и II, а также в виде полугидрата и применение этого соединения как лекарственного средства.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10339862A DE10339862A1 (de) | 2003-08-29 | 2003-08-29 | 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)- phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester-Methansulfonat und dessen Verwendung als Arzneimittel |
Publications (1)
Publication Number | Publication Date |
---|---|
UA85686C2 true UA85686C2 (ru) | 2009-02-25 |
Family
ID=34202202
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
UAA200603253A UA85686C2 (ru) | 2003-08-29 | 2004-08-24 | Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения |
Country Status (36)
Country | Link |
---|---|
US (2) | US20050234104A1 (ru) |
EP (2) | EP2060569B1 (ru) |
JP (2) | JP5348842B2 (ru) |
KR (1) | KR101331039B1 (ru) |
CN (2) | CN1845917B (ru) |
AR (2) | AR045520A1 (ru) |
AT (2) | ATE529420T1 (ru) |
AU (2) | AU2004274139B2 (ru) |
BR (1) | BRPI0413849A (ru) |
CA (2) | CA2537054C (ru) |
CO (1) | CO5660265A2 (ru) |
CY (2) | CY1109299T1 (ru) |
DE (2) | DE10339862A1 (ru) |
DK (2) | DK2060569T3 (ru) |
EA (1) | EA009736B1 (ru) |
EC (2) | ECSP066399A (ru) |
ES (2) | ES2375896T3 (ru) |
HK (2) | HK1096682A1 (ru) |
HR (2) | HRP20090311T1 (ru) |
IL (1) | IL173885A (ru) |
ME (1) | ME00340B (ru) |
MX (1) | MXPA06001959A (ru) |
MY (2) | MY145696A (ru) |
NO (2) | NO334115B1 (ru) |
NZ (2) | NZ545984A (ru) |
PE (1) | PE20050348A1 (ru) |
PL (2) | PL1660482T3 (ru) |
PT (2) | PT2060569E (ru) |
RS (2) | RS53370B (ru) |
SG (1) | SG145734A1 (ru) |
SI (2) | SI1660482T1 (ru) |
TW (2) | TWI375674B (ru) |
UA (1) | UA85686C2 (ru) |
UY (2) | UY28493A1 (ru) |
WO (1) | WO2005028468A1 (ru) |
ZA (1) | ZA200600518B (ru) |
Families Citing this family (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
US20050070537A1 (en) * | 2002-10-10 | 2005-03-31 | Chris Rundfeldt | Use of dihydroimidazolones for the treatment of dogs |
DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
DE102005020002A1 (de) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
DE102005025728A1 (de) * | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester |
DE102006054005A1 (de) * | 2006-11-16 | 2008-05-21 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
CN101980697A (zh) * | 2008-03-28 | 2011-02-23 | 贝林格尔.英格海姆国际有限公司 | 制备口服给药的达比加群制剂的方法 |
NZ589746A (en) | 2008-07-14 | 2012-10-26 | Boehringer Ingelheim Int | Method for manufacturing medicinal compounds containing dabigatran |
EP2328581A1 (en) * | 2008-08-19 | 2011-06-08 | Boehringer Ingelheim International GmbH | Use of dabigatranetexilate for treating patients with pulmonary hypertension |
CN103356614A (zh) | 2008-11-11 | 2013-10-23 | 贝林格尔.英格海姆国际有限公司 | 使用达比加群酯或其盐治疗或预防血栓形成且与常规华法林疗法相比具有改良安全性的方法 |
WO2010130757A1 (en) | 2009-05-14 | 2010-11-18 | Boehringer Ingelheim International Gmbh | New combination therapy in treatment of oncological and fibrotic diseases |
HUP1000069A2 (en) * | 2010-02-02 | 2012-05-02 | Egis Gyogyszergyar Nyilvanosan M Kod Ruszvunytarsasag | New salts for the preparation of pharmaceutical composition |
SI2542224T1 (sl) * | 2010-03-01 | 2014-10-30 | Ratiopharm Gmbh | Oralni farmacevtski sestavek, ki vsebuje dabigatran eteksilat |
JP2013521318A (ja) | 2010-03-08 | 2013-06-10 | ラティオファルム ゲー・エム・ベー・ハー | ダビガトランエテキシラートを含有する医薬組成物 |
PT2588090T (pt) | 2010-07-01 | 2017-06-26 | Krka Tovarna Zdravil D D Novo Mesto | Formas de dosagem oral farmacêuticas compreendendo dabigatrano etexilato e os seus sais farmaceuticamente aceitáveis |
WO2012027543A1 (en) | 2010-08-25 | 2012-03-01 | Teva Pharmaceuticals Usa, Inc. | Solid state forms of dabigatran etexilate, dabigatran etexilate mesylate and processes for preparation thereof |
ES2550771T3 (es) | 2010-09-27 | 2015-11-12 | Ratiopharm Gmbh | Sal de bismesilato etexilato de dabigatrán, formas en estado sólido y proceso para la preparación de las mismas |
EP2649060B1 (en) * | 2010-12-06 | 2017-04-05 | MSN Laboratories Limited | Process for the preparation of benzimidazole derivatives and its salts |
HUP1100244A2 (hu) | 2011-05-11 | 2012-11-28 | Egis Gyogyszergyar Nyilvanosan Muekoedoe Reszvenytarsasag | Gyógyszeripari intermedierek és eljárás elõállításukra |
WO2012162492A1 (en) | 2011-05-24 | 2012-11-29 | Teva Pharmaceutical Industries Ltd. | Compressed core comprising organic acids for a pharmaceutical composition |
MX2014007331A (es) | 2011-12-22 | 2014-09-01 | Boehringer Ingelheim Int | Sistema de multiunidades de granulos de liberacion inmediata. |
WO2013111163A2 (en) | 2012-01-20 | 2013-08-01 | Cadila Healthcare Limited | Process for the preparation of dabigatran etexilate mesylate and polymorphs of intermediates thereof |
JP2015504903A (ja) | 2012-01-24 | 2015-02-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 新規の経口投与用ダビガトラン製剤 |
ES2895918T3 (es) | 2012-02-21 | 2022-02-23 | Towa Pharmaceutical Europe S L | Composiciones farmacéuticas orales de dabigatrán etexilato |
EP2631234A1 (en) | 2012-02-23 | 2013-08-28 | Esteve Química, S.A. | Solid forms of dabigatran etexilate mesylate and processes for their preparation |
WO2013144971A1 (en) | 2012-03-27 | 2013-10-03 | Cadila Healthcare Limited | New solid forms of dabigatran etexilate bisulfate and mesylate and processes to prepare them |
US9273030B2 (en) | 2012-04-02 | 2016-03-01 | Msn Laboratories Private Limited | Process for the preparation of benzimidazole derivatives and salts thereof |
EP2872499A1 (en) * | 2012-07-16 | 2015-05-20 | Interquim, S.A. | Process for the preparation of intermediates for the synthesis of dabigatran etexilate, and crystalline forms of said intermediates |
US9150542B2 (en) | 2012-08-31 | 2015-10-06 | Ranbaxy Laboratories Limited | Process for the preparation of crystalline form I of methanesulfonate salt of dabigatran etexilate |
CN103664882A (zh) * | 2012-09-20 | 2014-03-26 | 天津药物研究院 | 结晶变体形态的达比加群酯及其制备方法和用途 |
CN103864756B (zh) * | 2012-12-11 | 2018-06-15 | 四川海思科制药有限公司 | 丁二磺酸达比加群酯及其制备方法和用途 |
EP2835370A1 (en) | 2013-08-08 | 2015-02-11 | Medichem, S.A. | New crystals of dabigatran etexilate mesylate |
CN104418840A (zh) * | 2013-09-05 | 2015-03-18 | 天津汉瑞药业有限公司 | 甲磺酸达比加群酯无水化合物 |
WO2015128875A2 (en) | 2014-02-26 | 2015-09-03 | Megafine Pharma (P) Ltd. | A process for preparation of dabigatran etexilate mesylate and intermediates thereof |
CN104892574A (zh) * | 2014-03-04 | 2015-09-09 | 浙江海正药业股份有限公司 | 达比加群酯甲磺酸盐的晶型及其制备方法和用途 |
US9820988B2 (en) | 2014-03-24 | 2017-11-21 | Boehringer Ingelheim Vetmedica Gmbh | Treatment of epileptic disorders in feline animals |
CN104974137A (zh) * | 2014-04-04 | 2015-10-14 | 江苏天士力帝益药业有限公司 | 达比加群酯甲磺酸盐新晶型及其制备方法 |
CN105461686A (zh) * | 2014-08-25 | 2016-04-06 | 江苏豪森药业股份有限公司 | 制备高纯度甲磺酸达比加群酯晶型的方法 |
CN104825422B (zh) * | 2014-09-29 | 2017-12-12 | 普济生物科技(台州)有限公司 | 含达比加群酯甲磺酸盐的药物组合物及其制备方法 |
EP4205743A1 (en) | 2014-12-31 | 2023-07-05 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical composition and preparation method therefor |
CN104725360A (zh) * | 2015-04-09 | 2015-06-24 | 重庆东得医药科技有限公司 | 一种甲磺酸达比加群酯ⅰ晶型的制备方法 |
WO2017111637A1 (en) | 2015-12-23 | 2017-06-29 | Zaklady Farmaceutyczne Polpharma Sa | Pharmaceutical composition comprising dabigatran or a pharmaceutically acceptable salt thereof |
US10449195B2 (en) | 2016-03-29 | 2019-10-22 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical formulation of palbociclib and a preparation method thereof |
CN107778291A (zh) * | 2016-08-31 | 2018-03-09 | 亚宝药业集团股份有限公司 | 一种甲磺酸达比加群酯晶型ⅱ的制备方法 |
WO2020092139A1 (en) | 2018-10-29 | 2020-05-07 | Huahai Us Inc. | Novel dipeptide compounds and uses thereof |
JP2020193184A (ja) * | 2019-05-30 | 2020-12-03 | ダイト株式会社 | ダビガトランエテキシラートメタンスルホン酸塩の形態iの製造方法 |
EP3771465A1 (en) | 2019-08-01 | 2021-02-03 | Zaklady Farmaceutyczne Polpharma SA | Pharmaceutical composition comprising dabigatran etexilate |
CN114306245A (zh) | 2020-09-29 | 2022-04-12 | 深圳市药欣生物科技有限公司 | 无定形固体分散体的药物组合物及其制备方法 |
CN114380793B (zh) * | 2020-10-20 | 2024-02-23 | 北京澳合药物研究院有限公司 | 一种甲磺酸达比加群酯晶型i的制备方法及其应用 |
US11446286B1 (en) * | 2022-02-28 | 2022-09-20 | King Faisal University | Treatment of fungal infections using dabigatran etexilate |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6087380A (en) * | 1949-11-24 | 2000-07-11 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparations and the use thereof as pharmaceutical compositions |
US4427468A (en) * | 1976-01-16 | 1984-01-24 | Her Majesty The Queen In Right Of Canada | Curable propellant binding systems with bonding agent combination |
DE3000979A1 (de) * | 1980-01-12 | 1981-07-23 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue dipyridamol-retardformen und verfahren zu ihrer herstellung |
DE3124090A1 (de) * | 1981-06-19 | 1983-01-05 | Dr. Karl Thomae Gmbh, 7950 Biberach | Neue orale dipyridamolformen |
DE3126703A1 (de) * | 1981-07-07 | 1983-01-27 | Dr. Karl Thomae Gmbh, 7950 Biberach | Bromhexin-retardform und verfahren zu ihrer herstellung |
JPS58134033A (ja) | 1982-02-02 | 1983-08-10 | Fujisawa Pharmaceut Co Ltd | 医薬組成物 |
US4675405A (en) * | 1984-09-21 | 1987-06-23 | American Home Products Corporation | Quinoline compounds as antiallergic and antithrombotic agents |
DE4129603A1 (de) * | 1991-09-06 | 1993-03-11 | Thomae Gmbh Dr K | Kondensierte 5-gliedrige heterocyclen, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel |
US5416099A (en) * | 1991-10-29 | 1995-05-16 | Merck & Co., Inc. | Fibrinogen receptor antagonists |
ZA928276B (en) | 1991-10-31 | 1993-05-06 | Daiichi Seiyaku Co | Aromatic amidine derivates and salts thereof. |
SG42869A1 (en) * | 1992-08-05 | 1997-10-17 | Faulding F H & Co Ltd | Pelletised pharmaceutical composition |
JPH06340619A (ja) | 1993-05-03 | 1994-12-13 | Bristol Myers Squibb Co | グアニジニルまたはアミジニル置換メチルアミノ複素環トロンビン抑制剤 |
CA2134192A1 (en) | 1993-11-12 | 1995-05-13 | Michael L. Denney | 5, 6-bicyclic glycoprotein iib/iiia antagonists |
PE121699A1 (es) * | 1997-02-18 | 1999-12-08 | Boehringer Ingelheim Pharma | Heterociclos biciclicos disustituidos como inhibidores de la trombina |
US6414008B1 (en) * | 1997-04-29 | 2002-07-02 | Boehringer Ingelheim Pharma Kg | Disubstituted bicyclic heterocycles, the preparation thereof, and their use as pharmaceutical compositions |
DE19752843C2 (de) | 1997-11-28 | 2003-01-09 | Byk Gulden Lomberg Chem Fab | Arzneimittelzubereitung in Tabletten- oder Pelletform für Pantoprazol und Omeprazol |
DE10133786A1 (de) | 2001-07-16 | 2003-02-06 | Boehringer Ingelheim Pharma | Verwendung von Thrombin-Inhibitoren zur Behandlung von Arthritis |
US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
DE10245624A1 (de) * | 2002-09-30 | 2004-04-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Oral zu applizierende Darreichungsform für 3-[(2-{[4-(Hexyloxycarbonylaminoimino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2yl-amino]-propinsäure-ethylester und dessen Salze |
US20030181488A1 (en) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Administration form for the oral application of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester and the salts thereof |
PT1870100E (pt) * | 2002-03-07 | 2012-04-17 | Boehringer Ingelheim Int | Metanossulfonato de 3-[(2-{[4-(hexiloxicarbonilamino-iminometil)- fenilamino]-metil}-1-metil-1h-benzimidazol-5-carbonil)- piridin-2-il-amino]-propionato de etilo |
DE10209982A1 (de) * | 2002-03-07 | 2003-09-25 | Boehringer Ingelheim Pharma | Oral zu applizierende Darreichungsform für schwerlösliche basische Wirkstoffe |
DE10235639A1 (de) * | 2002-08-02 | 2004-02-19 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue Prodrugs von 1-Methyl-2-(4-amidinophenylaminomethyl)-benzimidazol-5-yl-carbonsäure-(N-2-pyridyl-N-2-hydroxycarbonylethyl)-amid, ihre Herstellung und ihre Verwendung als Arzneimittel |
RU2005136383A (ru) * | 2003-04-24 | 2007-06-10 | БЕРИНГЕР ИНГЕЛЬХАЙМ ИНТЕРНАЦИОНАЛЬ ГмбХ (DE) | Применение дипиридамола или мопидамола для лечения и предупреждения тромбоэмболических заболеваний и нарушений, вызываемыхизбыточным образованием и/или повышенным уровнем экспрессии тромбиновых рецепторов |
DE10337697A1 (de) * | 2003-08-16 | 2005-03-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Tablette enthaltend 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenyl-amino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester oder dessen Salze |
US20050107438A1 (en) * | 2003-09-03 | 2005-05-19 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition comprising 3-[(2-{[4-(Hexyloxycarbonylaminoiminomethyl) phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester or a salt therefore |
EP1609784A1 (de) * | 2004-06-25 | 2005-12-28 | Boehringer Ingelheim Pharma GmbH & Co.KG | Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen |
US20060222640A1 (en) * | 2005-03-29 | 2006-10-05 | Boehringer Ingelheim International Gmbh | New pharmaceutical compositions for treatment of thrombosis |
DE102005020002A1 (de) * | 2005-04-27 | 2006-11-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Physiologisch verträgliche Salze von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionsäure-ethylester |
DE102005025728A1 (de) * | 2005-06-04 | 2006-12-07 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Polymorphe von 3-[(2-{[4-(Hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-Propionsäure-ethylester |
DE102005061623A1 (de) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von 4-(Benzimidazolylmethylamino)-Benzamidinen und deren Salzen |
DE102005061624A1 (de) * | 2005-12-21 | 2007-06-28 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verbessertes Verfahren zur Herstellung von Salzen von 4-(Benzimidazolylmethylamino)-Benzamidinen |
-
2003
- 2003-08-29 DE DE10339862A patent/DE10339862A1/de not_active Withdrawn
-
2004
- 2004-08-13 US US10/918,017 patent/US20050234104A1/en not_active Abandoned
- 2004-08-24 PT PT09153155T patent/PT2060569E/pt unknown
- 2004-08-24 SG SG200805933-9A patent/SG145734A1/en unknown
- 2004-08-24 AT AT09153155T patent/ATE529420T1/de active
- 2004-08-24 AU AU2004274139A patent/AU2004274139B2/en not_active Expired
- 2004-08-24 SI SI200431177T patent/SI1660482T1/sl unknown
- 2004-08-24 EP EP09153155A patent/EP2060569B1/de not_active Revoked
- 2004-08-24 RS RS20060136A patent/RS53370B/en unknown
- 2004-08-24 UA UAA200603253A patent/UA85686C2/ru unknown
- 2004-08-24 DK DK09153155.8T patent/DK2060569T3/da active
- 2004-08-24 PL PL04764411T patent/PL1660482T3/pl unknown
- 2004-08-24 ES ES09153155T patent/ES2375896T3/es not_active Expired - Lifetime
- 2004-08-24 MX MXPA06001959A patent/MXPA06001959A/es active IP Right Grant
- 2004-08-24 CN CN2004800249521A patent/CN1845917B/zh not_active Expired - Lifetime
- 2004-08-24 CN CN2011100536316A patent/CN102167695B/zh not_active Expired - Lifetime
- 2004-08-24 EP EP04764411A patent/EP1660482B1/de not_active Expired - Lifetime
- 2004-08-24 SI SI200431794T patent/SI2060569T1/sl unknown
- 2004-08-24 DE DE502004009431T patent/DE502004009431D1/de not_active Expired - Lifetime
- 2004-08-24 RS YUP-2006/0136A patent/RS20060136A/sr unknown
- 2004-08-24 BR BRPI0413849-0A patent/BRPI0413849A/pt not_active Application Discontinuation
- 2004-08-24 AT AT04764411T patent/ATE430145T1/de active
- 2004-08-24 EA EA200600381A patent/EA009736B1/ru not_active IP Right Cessation
- 2004-08-24 KR KR1020067003994A patent/KR101331039B1/ko active IP Right Grant
- 2004-08-24 CA CA2537054A patent/CA2537054C/en not_active Expired - Lifetime
- 2004-08-24 NZ NZ545984A patent/NZ545984A/en not_active IP Right Cessation
- 2004-08-24 ME MEP-2008-506A patent/ME00340B/me unknown
- 2004-08-24 PL PL09153155T patent/PL2060569T3/pl unknown
- 2004-08-24 WO PCT/EP2004/009432 patent/WO2005028468A1/de active Application Filing
- 2004-08-24 JP JP2006524316A patent/JP5348842B2/ja not_active Expired - Lifetime
- 2004-08-24 PT PT04764411T patent/PT1660482E/pt unknown
- 2004-08-24 CA CA2749579A patent/CA2749579C/en not_active Expired - Lifetime
- 2004-08-24 ES ES04764411T patent/ES2326654T3/es not_active Expired - Lifetime
- 2004-08-24 NZ NZ578586A patent/NZ578586A/en not_active IP Right Cessation
- 2004-08-24 DK DK04764411T patent/DK1660482T3/da active
- 2004-08-26 MY MYPI20093734A patent/MY145696A/en unknown
- 2004-08-26 MY MYPI20043499A patent/MY145632A/en unknown
- 2004-08-27 PE PE2004000824A patent/PE20050348A1/es not_active Application Discontinuation
- 2004-08-27 TW TW093125929A patent/TWI375674B/zh not_active IP Right Cessation
- 2004-08-27 AR ARP040103089A patent/AR045520A1/es active Pending
- 2004-08-27 UY UY28493A patent/UY28493A1/es not_active Application Discontinuation
- 2004-08-27 TW TW100125555A patent/TWI418553B/zh not_active IP Right Cessation
-
2006
- 2006-01-18 ZA ZA2006/00518A patent/ZA200600518B/en unknown
- 2006-02-23 IL IL173885A patent/IL173885A/en active IP Right Grant
- 2006-02-28 CO CO06019918A patent/CO5660265A2/es not_active Application Discontinuation
- 2006-03-01 EC EC2006006399A patent/ECSP066399A/es unknown
- 2006-03-28 NO NO20061420A patent/NO334115B1/no not_active IP Right Cessation
-
2007
- 2007-03-15 HK HK07102805.4A patent/HK1096682A1/xx not_active IP Right Cessation
- 2007-03-15 HK HK11112042.0A patent/HK1157760A1/xx not_active IP Right Cessation
-
2008
- 2008-01-30 US US12/022,655 patent/US7932273B2/en active Active
-
2009
- 2009-05-27 HR HR20090311T patent/HRP20090311T1/xx unknown
- 2009-07-23 CY CY20091100788T patent/CY1109299T1/el unknown
- 2009-08-28 AR ARP090103316A patent/AR073225A2/es unknown
- 2009-12-18 UY UY0001032342A patent/UY32342A/es not_active Application Discontinuation
-
2010
- 2010-04-13 AU AU2010201457A patent/AU2010201457B2/en not_active Expired
-
2011
- 2011-05-09 JP JP2011104428A patent/JP5566332B2/ja not_active Expired - Lifetime
- 2011-11-21 EC EC2011006399A patent/ECSP11006399A/es unknown
-
2012
- 2012-01-10 HR HR20120028T patent/HRP20120028T1/hr unknown
- 2012-01-11 CY CY20121100024T patent/CY1112222T1/el unknown
-
2013
- 2013-06-05 NO NO20130778A patent/NO20130778L/no not_active Application Discontinuation
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
UA85686C2 (ru) | Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}- 1-метил-1h-бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и его применение как лекарственного средства, способ его получения | |
RS79204A (en) | Form of presentation for 3-/(2-(/4- (hexyloxycarbonylamino- imino- methyl)-phenylamino/-methyl)-1-methyl- 1h-benzimidazol -5-carbonyl)pyridin-2-yl- amino/propionic acid ethyl ester to be administered orally | |
CY1108218T1 (el) | Δισκιο που περιεχει 3-[(2-{[4-(εξυλοξυκαρβονυλαμινο-ιμινο-μεθυλο)-φαινυλαμινο]-μεθυλο}-1 -μεθυλο-1 η-βενζιμιδαζολο5-καρβονυλο)-πυριδιν-2-υλ-αμινο] προπιονικο αιθυλεστερα | |
TW200637822A (en) | Process for the preparation of a 2-pyridylethylcarboxamide derivative | |
TW200606144A (en) | Crystal of 1,2-dihydropyridine compound | |
TW200633981A (en) | Process for the preparation of a 2-ethylaminopyridine derivative | |
TW200716610A (en) | Physiologically acceptable salts of 3-[(2-{[4-(hexyloxycarbonylamino-imino-methyl)-phenylamino]-methyl}-1-methyl-1H-benzimidazol-5-carbonyl)-pyridin-2-yl-amino]-propionic acid ethyl ester | |
TW200700416A (en) | 'n-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl]-2-methyl-4-pyrimidinyl]amino]-5-thiazolecarboxamides metabolites | |
IL183700A0 (en) | Process for production of (4,5-dihydroisoxazol-3-yl)thio-carboxamidine salts | |
WO2008011483A3 (en) | Methods for treating chronic pain using 1- (hetero) aryl-1-hydroxy 2,3-diamino-propyl amines and related compounds | |
UA97648C2 (ru) | N-(2-гидроксиэтил)-n-метил-4-(хинолин-8-ил(1-(тиазол-4-илметил)пиперидин-4-илиден)метил)бензамид, способ его получения (варианты), фармацевтическая композиция и его применение для подавления боли или для лечения депрессии, тревожности или болезни паркинсона | |
TW200833337A (en) | Succinate salt of 2-((4-(1-methyl-4-(pyridin-4-yl)-1H-pyrazol-3-yl)phenoxy)methyl)quinoline | |
AU2003235814A8 (en) | Novel process for the preparation of trans-3- ethyl-2,5- dihydro-4- methyl-n-(2-( 4-(((((4-methyl cyclohexyl) amino)carbonyl) amino)sulfonyl) phenyl)ethyl) -2-oxo-1h-pyrrole -1-carboxamide | |
SI1315723T1 (en) | The hydrochloride salt of 5(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4-dione | |
UA95601C2 (ru) | Метансульфонат этилового эфира 3-[(2-{[4-(гексилоксикарбониламиноиминометил)фениламино]метил}-1метил-1н- бензимидазол-5-карбонил)пиридин-2-иламино]пропионовой кислоты и фармацевтическая композиция, которая его содержит | |
AU2003244922A1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-methyl-3-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating pulmonary fibrosis | |
IL182445A0 (en) | Process for the preparation of n-(3,5-dichloropyrid-4-yl)-4difluoromethoxy-8-methanesulfona mido-dibenzo[b,d]furan-1-caboxamide | |
UA101816C2 (en) | Polymorphic forms of n-[4-(trifluoromethyl)benzyl]-4-methoxybutyramide | |
EP1806344A4 (en) | OPTICALLY ACTIVE 4,4-DISUBSTITUTED OXAZOLIDINE DERIVATIVE AND SYNTHESIS METHOD OF SAID DERIVATIVE | |
IL153280A0 (en) | 5-(4-(2-(n-methyl-n-(2-pyridyl)amino)ethoxy)benzyl)thiazolidine-2,4 dione hydriodide as pharmaceutical | |
WO2008005955A8 (en) | Synthesis of heterocyclic compounds | |
AU2003232376A1 (en) | 4-(4-methylpiperazin-1-ylmethyl)-n-(4-pyridin-3-yl)pyrimidin-2-ylamino)phenyl)-benzamide for treating anaplastic thyroid cancer | |
ZA200806371B (en) | Process for preparing [2-(2,3-dihydrobenzofuran- or benzofuran-7-yloxy)ethyl]-(3-cyclopent-1-ylbenzyl)amine derivatives and synthesis intermediate | |
MX2007000892A (es) | Un hidrato variable cristalino de la sal de (s)-3-piridincarboxami da, 6-[4-[2-[[3-(9h-carbazol-4-iloxi)-2-hidroxipropil]amino]-2-met ilpropil]fenoxi]-hemisuccinato. | |
PL374074A1 (pl) | Sposób wytwarzania krystalicznej formy Ó monomesylanu 4-(4-metylopiperazyn-1-ylometylo)-N-[4-metylo-3-[(4-pirydyn-3-ylo)pirymidyn-2-yloamino]fenylo]benzamidu |